KNOTUS Co.Ltd Total Liabilities

Latest as of September 2025: ₩44.24 Billion KRW ≈ $29.98 Million USD

KNOTUS Co.Ltd total liabilities. Based on the latest financial reports, KNOTUS Co.Ltd (278650) has total liabilities worth ₩44.24 Billion KRW (≈ $29.98 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check 278650 cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.

Total Liabilities of KNOTUS Co.Ltd (2016–2024)

Total liabilities of KNOTUS Co.Ltd from 2016 to 2024. This chart illustrates how KNOTUS Co.Ltd's total liabilities have evolved over time, based on quarterly financial data.

KNOTUS Co.Ltd Competitors by Total Liabilities

The table below lists competitors of KNOTUS Co.Ltd ranked by their total liabilities.

Company Country Total Liabilities
BLS E-Services Limited
NSE:BLSE
India Rs-5.70 Billion
Afrimat
JSE:AFT
South Africa ZAC4.82 Billion
Syncmold Enterprise Corp
TW:1582
Taiwan NT$5.20 Billion
Green Cross
KO:005250
Korea ₩2.40 Trillion
Metrodata Electronics Tbk
JK:MTDL
Indonesia Rp8.10 Trillion
Vaibhav Global Limited
NSE:VAIBHAVGBL
India Rs-16.48 Billion
Kitex Garments Limited
NSE:KITEX
India Rs-12.39 Billion
Nanjing Chixia Development Co Ltd
SHG:600533
China CN¥14.53 Billion

Liability Composition Analysis (2016–2024)

This chart breaks down KNOTUS Co.Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see total assets of KNOTUS Co.Ltd.

Liquidity & Leverage Metrics

KNOTUS Co.Ltd Total Liabilities Ratios Explained

KNOTUS Co.Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.

Metric Value Description
Current Ratio 1.29 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.41 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.28 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how KNOTUS Co.Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for KNOTUS Co.Ltd (2016–2024)

The table below shows the annual total liabilities of KNOTUS Co.Ltd from 2016 to 2024.

Year Total Liabilities Change
2024-12-31 ₩56.45 Billion
≈ $38.26 Million
-17.15%
2023-12-31 ₩68.14 Billion
≈ $46.18 Million
-33.14%
2022-12-31 ₩101.91 Billion
≈ $69.06 Million
+239.26%
2021-12-31 ₩30.04 Billion
≈ $20.36 Million
+46.02%
2020-12-31 ₩20.57 Billion
≈ $13.94 Million
+4.60%
2019-12-31 ₩19.67 Billion
≈ $13.33 Million
-14.76%
2018-12-31 ₩23.07 Billion
≈ $15.64 Million
+38.33%
2017-12-31 ₩16.68 Billion
≈ $11.30 Million
+49.28%
2016-12-31 ₩11.17 Billion
≈ $7.57 Million
--

About KNOTUS Co.Ltd

KQ:278650 Korea Biotechnology
Market Cap
$290.80 Million
₩429.11 Billion KRW
Market Cap Rank
#14723 Global
#467 in Korea
Share Price
₩5080.00
Change (1 day)
-22.68%
52-Week Range
₩1099.00 - ₩6870.00
All Time High
₩36886.01
About

HLB bioStep Co.,Ltd. provides various test services in South Korea. It offers non clinical CRO services for cancer, bone and brain disease, endocrineand metabolic and eye disease, liver and circulatory system disease, dental and gastrointestinal disease, hair growth, kidney and respiratory disease, painmodel, and skin disease. It also offers representative analysis equipment, veterinary drug deve… Read more